Search results
Results From The WOW.Com Content Network
The Invisalign Express 10, which uses 10 aligners, was introduced in 2005. [14] Invisalign 1.5 was released in 2009. It was followed by Invisalign G3 in 2010 and G4 in 2011. Invisalign G3 and G4 were designed for more complex treatments. An Invisalign Express 5 version, which uses 5 aligners, was introduced in 2012. [15]
Invisalign is manufactured by Align Technology, an American multinational medical-device company. The company's clear align system has been used to treat more than 12.2 million patients. [2] The company was founded in 1997 by Zia Chishti. Chishti conceived of the basic design of InvisAlign while an adult orthodontics patient.
Fee-for-service (FFS) is a payment model where services are unbundled and paid for separately. [ 1 ] In health care, it gives an incentive for physicians to provide more treatments because payment is dependent on the quantity of care, rather than quality of care.
Dental implant, 3D illustration. A dental implant (also known as an endosseous implant or fixture) is a prosthesis that interfaces with the bone of the jaw or skull to support a dental prosthesis such as a crown, bridge, denture, or facial prosthesis or to act as an orthodontic anchor.
RBRVS was created at Harvard University in their national RBRVS study from December 1985 and published in JAMA on September 29, 1988. [6] William Hsiao was the principal investigator who organized a multi-disciplinary team of researchers, which included statisticians, physicians, economists and measurement specialists, to develop the RBRVS.
Dental braces. Dental braces (also known as orthodontic braces, or simply braces) are devices used in orthodontics that align and straighten teeth and help position them with regard to a person's bite, while also aiming to improve dental health.
The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process.
The Energy Innovation and Carbon Dividend Act of 2023 (H.R. 5744) is a bill in the United States House of Representatives that proposes a fee on carbon at the point of extraction to encourage market-driven innovation of clean energy technologies to reduce greenhouse gas emissions. The fees are recycled to citizens in monthly dividends.